May 15, 2025 12:39 PM EDT
FDA+

FDA warns Mayne Phar­ma over 'mis­lead­ing' pre­sen­ta­tion slides on birth con­trol pill

Zachary Brennan

Senior Editor

The FDA’s drug pro­mo­tion of­fice is call­ing out Aus­tralia’s Mayne Phar­ma for mak­ing “false or mis­lead­ing claims” about the ben­e­fits and risks of its birth …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

Bris­tol My­ers CEO says Amer­i­ca’s bio­phar­ma pole po­si­tion is not guar­an­teed

New CBER chief Prasad is ready­ing 'mas­sive frame­work' around vac­cines, Makary says

Ex­clu­sive: Drug com­pounder Em­pow­er was built on risky short­cuts, ex-em­ploy­ees and in­spec­tions al­lege

Bio­haven stock sinks on three-month de­lay for neu­ro drug's FDA ap­proval de­ci­sion

Pathos AI col­lects $365M to fu­el 'bul­let­proof' on­col­o­gy tri­als and in-li­cense more can­cer drugs

A service from the Financial Times